| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SNO; SnoA; SnoI; SnoN |
| WB Predicted band size | 77 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human SKIL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL9R抗体的3篇参考文献及其摘要概述：
1. **"Anti-IL-9 Antibody Treatment Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Models"**
- **作者**: Kearley, J. et al.
- **摘要**: 研究通过小鼠哮喘模型证明，靶向IL-9受体(IL9R)的单克隆抗体可显著减少嗜酸性粒细胞浸润、黏液分泌及气道高反应性，提示IL9R抗体在过敏性哮喘治疗中的潜力。
2. **"IL-9 Receptor Signaling in T Cells and Mast Cells Drives Psoriasis-like Skin Inflammation"**
- **作者**: Singh, T.P. et al.
- **摘要**: 该文献发现IL9R在银屑病患者的Th9细胞和肥大细胞中高表达，使用抗IL9R抗体可阻断IL-9信号传导，显著减轻小鼠模型中的皮肤炎症和角质化过度。
3. **"Targeting IL-9/IL-9R Signaling in Tumor-Associated Immunity Suppresses Colorectal Cancer Growth"**
- **作者**: Purwar, R. et al.
- **摘要**: 研究显示，IL9R在结直肠癌微环境的调节性T细胞(Treg)中高表达，抗IL9R抗体通过抑制Treg功能并增强抗肿瘤免疫反应，显著减缓小鼠肿瘤进展。
4. **"IL-9 Promotes Allergic Inflammation by Enhancing Mast Cell Activation via IL-9R"**
- **作者**: Goswami, R. et al.
- **摘要**: 该研究揭示IL9R在肥大细胞上的表达与过敏反应相关，阻断IL9R可抑制肥大细胞脱颗粒和组胺释放，为抗IL9R抗体治疗食物过敏等疾病提供理论依据。
以上研究均聚焦于IL9R抗体在不同疾病模型中的治疗机制，涵盖哮喘、银屑病、癌症及过敏反应等方向。
The interleukin-9 receptor (IL-9R) is a cell surface protein belonging to the cytokine receptor superfamily, primarily expressed on immune cells such as T helper 2 (Th2) cells, mast cells, and eosinophils. It consists of a unique IL-9-specific α-chain (IL-9Rα) and a common γ-chain shared with other cytokine receptors. IL-9R signaling, mediated through the JAK-STAT pathway, plays a critical role in allergic inflammation, autoimmune disorders, and cancer progression by regulating cell proliferation, survival, and cytokine production.
IL-9R antibodies are therapeutic or research tools designed to block IL-9/IL9R interactions. In diseases like asthma and atopic dermatitis, IL-9 overexpression correlates with pathological immune activation. Antibodies targeting IL-9R aim to disrupt this signaling, potentially reducing inflammation and tissue damage. Preclinical studies in murine models have shown that anti-IL9R antibodies can attenuate airway hyperresponsiveness and eosinophil infiltration. In oncology, IL-9R is investigated as a target in T-cell lymphomas and solid tumors where IL-9 promotes tumor growth or immune evasion.
Current challenges include optimizing antibody specificity to avoid off-target effects and understanding the receptor's dual role in pro- and anti-inflammatory responses. Several monoclonal antibodies are in early-stage clinical trials, reflecting growing interest in IL-9R as a therapeutic checkpoint. However, its complex biology necessitates careful evaluation of therapeutic benefits versus potential immunosuppressive risks.
×
